Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Silo Pharma (SILO) over the last 13 years, with Q3 2025 value amounting to -$1.1 million.

  • Silo Pharma's Income from Continuing Operations fell 1955.44% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.1 million, marking a year-over-year decrease of 3669.93%. This contributed to the annual value of -$4.4 million for FY2024, which is 2097.99% down from last year.
  • According to the latest figures from Q3 2025, Silo Pharma's Income from Continuing Operations is -$1.1 million, which was down 1955.44% from -$1.2 million recorded in Q2 2025.
  • In the past 5 years, Silo Pharma's Income from Continuing Operations registered a high of $6.5 million during Q3 2021, and its lowest value of -$1.8 million during Q1 2023.
  • For the 5-year period, Silo Pharma's Income from Continuing Operations averaged around -$664721.9, with its median value being -$1.0 million (2023).
  • Examining YoY changes over the last 5 years, Silo Pharma's Income from Continuing Operations showed a top increase of 126312.85% in 2021 and a maximum decrease of 26166.02% in 2021.
  • Over the past 5 years, Silo Pharma's Income from Continuing Operations (Quarter) stood at -$1.1 million in 2021, then tumbled by 56.46% to -$1.7 million in 2022, then surged by 36.76% to -$1.1 million in 2023, then plummeted by 64.57% to -$1.7 million in 2024, then soared by 35.84% to -$1.1 million in 2025.
  • Its Income from Continuing Operations was -$1.1 million in Q3 2025, compared to -$1.2 million in Q2 2025 and -$1.0 million in Q1 2025.